4.5 Article

Fenugreek A naturally occurring edible spice as an anticancer agent

期刊

CANCER BIOLOGY & THERAPY
卷 8, 期 3, 页码 268-274

出版社

TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.8.3.7443

关键词

dietary bioactive agents; fenugreek; diosgenin; prostate cancer; breast cancer; pancreatic cancer and phosphorylation

类别

资金

  1. NCI SPORE [P50CA58236]
  2. Prostate Cancer Foundation
  3. AEGON International Fellowship in Oncology
  4. FAMRI

向作者/读者索取更多资源

In recent years, various dietary components that can potentially be used for the prevention and treatment of cancer have been identified. In this study, we demonstrate that extract (FE) from the seeds of the plant Trigonella foenum graecum, commonly called fenugreek, are cytotoxic in vitro to a panel of cancer but not normal cells. Treatment with 10-15 ug/mL of FE for 72 h was growth inhibitory to breast, pancreatic and prostate cancer cell lines (PCa). When tested at higher doses (15-20 ug/mL), FE continued to be growth inhibitory to PCa cell lines but not to either primary prostate or htert-immortalized prostate cells. At least part of the growth inhibition is due to induction of cell death, as seen by incorporation of Ethidium Bromide III into cancer cells exposed to FE. Molecular changes induced in PCa cells are: in DU-145 cells: downregulation of mutant p53, and in PC-3 cells upregulation of p21 and inhibition of TGF beta induced phosphorylation of Akt. The surprising finding of our studies is that death of cancer cells occurs despite growth stimulatory pathways being simultaneously upregulated (phosphorylated) by FE. Thus, these studies add another biologically active agent to our armamentarium of naturally occurring agents with therapeutic potential.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice

Miguel F. Sanmamed, Inmaculada Rodriguez, Kurt A. Schalper, Carmen Onate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea Morales-Kastresana, Sara Labiano, Jose L. Perez-Gracia, Salvador Martin-Algarra, Carlos Alfaro, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel, Ignacio Melero

CANCER RESEARCH (2015)

Article Oncology

Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function

N. V. Rajeshkumar, Prasanta Dutta, Shinichi Yabuuchi, Roeland F. de Wilde, Gary V. Martinez, Anne Le, Jurre J. Kamphorst, Joshua D. Rabinowitz, Sanjay K. Jain, Manuel Hidalgo, Chi V. Dang, Robert J. Gillies, Anirban Maitra

CANCER RESEARCH (2015)

Article Oncology

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Dejan Juric, Rodrigo Dienstmann, Andres Cervantes, Manuel Hidalgo, Wells Messersmith, George R. Blumenschein, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohorquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, Jose Baselga

CLINICAL CANCER RESEARCH (2015)

Article Oncology

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

Manuel Hidalgo, Carlos Plaza, Monica Musteanu, Peter Illei, Carrie B. Brachmann, Carla Heise, Daniel Pierce, Pedro P. Lopez-Casas, Camino Menendez, Josep Tabernero, Alfredo Romano, Xinyu Wei, Fernando Lopez-Rios, Daniel D. Von Hoff

CLINICAL CANCER RESEARCH (2015)

Article Oncology

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Erkan, Joerg Kleeff, Bruno Sainz, Christopher Heeschen

CLINICAL CANCER RESEARCH (2015)

Article Gastroenterology & Hepatology

Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment

Bruno Sainz, Sonia Alcala, Elena Garcia, Yolanda Sanchez-Ripoll, Maria M. Azevedo, Michele Cioffi, Marianthi Tatari, Irene Miranda-Lorenzo, Manuel Hidalgo, Gonzalo Gomez-Lopez, Marta Canamero, Mert Erkan, Joerg Kleeff, Susana Garcia-Silva, Patricia Sancho, Patrick C. Hermann, Christopher Heeschen

Article Gastroenterology & Hepatology

The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells

Michele Cioffi, Sara M. Trabulo, Yolanda Sanchez-Ripoll, Irene Miranda-Lorenzo, Enza Lonardo, Jorge Dorado, Catarina Reis Vieira, Juan Carlos Ramirez, Manuel Hidalgo, Alexandra Aicher, Stephan Hahn, Bruno Sainz, Christopher Heeschen

Article Oncology

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

Analia Azaro, Jordi Rodon, Antonio Calles, Irene Brana, Manuel Hidalgo, Pedro P. Lopez-Casas, Manuel Munoz, Paul Westwood, Joel Miller, Brian A. Moser, Ute Ohnmacht, William Bumgardner, Karim A. Benhadji, Emiliano Calvo

INVESTIGATIONAL NEW DRUGS (2015)

Article Oncology

Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer

Antonio Cubillo, Jesus Rodriguez-Pascual, Fernando Lopez-Rios, Carlos Plaza, Elena Garcia, Rafael Alvarez, Emilio de Vicente, Yolanda Quijano, Ovidio Hernando, Carmen Rubio, Sofia Perea, Gema Sanchez, Manuel Hidalgo

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)

Article Oncology

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart, Lee S. Rosen, Daniel W. Bowles

CLINICAL CANCER RESEARCH (2015)

Editorial Material Biochemistry & Molecular Biology

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

Joseph E. Grossman, Divya Vasudevan, Cailin E. Joyce, Manuel Hildago

ONCOGENE (2021)

Review Oncology

Facts and Hopes in Immunotherapy of Pancreatic Cancer

Bruno Bockorny, Joseph E. Grossman, Manuel Hidalgo

Summary: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging cancer to treat. Chemotherapy has limited benefits and immunotherapy has made little progress. However, recent advances in understanding the tumor microenvironment and new approaches to immunotherapy have provided hope. Improvements in preclinical models, targeting the tumor microenvironment, and identifying biomarkers will likely lead to better selection of patients who could benefit from immunotherapy. Urgent research is needed to design effective combination trials to cure patients with PDAC.

CLINICAL CANCER RESEARCH (2022)

Article Biochemistry & Molecular Biology

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer

Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T. H. Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P. Rocca, Allyson J. Ocean, Elizabeta C. Popa, Daniel H. Hunt, Nikhil P. Uppal, Kelly A. Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A. Shah, Erika Hissong

Summary: This study reports exceptional responses observed in patients with pMMR/MSS colon and rectal cancer treated with neoadjuvant botensilimab (BOT) and balstilimab (BAL). The findings have important implications for clinical trial designs using neoadjuvant immunotherapy and potentially sparing patients chemotherapy.

ONCOGENE (2023)

Article Biochemistry & Molecular Biology

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer

Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T. H. Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P. Rocca, Allyson J. Ocean, Elizabeta C. Popa, Daniel H. Hunt, Nikhil P. Uppal, Kelly A. Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A. Shah, Erika Hissong

Summary: Neoadjuvant botensilimab and balstilimab showed exceptional responses in patients with locally advanced mismatch repair proficient/microsatellite stable colon and rectal cancer. The observed rapid immune response pattern has not been previously described. Spatial biology analyses revealed the mechanism of action of botensilimab.

ONCOGENE (2023)

Article Oncology

A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas

Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A. Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M. Lowy, Laura Medina Rodriguez, Daniel Laheru, Beatriz Salvador-Barbero, Marcos Malumbres, David J. Shields, Joseph E. Grossman, Xin Huang, Meggan Tammaro, Jean-Francois Martini, Yanke Yu, Kenneth Kern, Teresa Macarulla

Summary: This study evaluates the clinical efficacy and safety of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma. The preclinical and clinical data suggest that this combination treatment has antitumor activity and tolerable toxicity, but does not meet the prespecified efficacy threshold.

CANCER RESEARCH COMMUNICATIONS (2022)

暂无数据